Long-term Follow-up of Pulmonary Function in Bronchial Asthma Patients Treated with Pranlukast

Lung

Volumn 182, Issue 1, 2004, Pages 51-58

  Yanagawa, H ^a,b   Sugita, A ^a   Azuma, M ^a   Ogawa, H ^a   Kitamuro, C ^a   Yoneda, K ^a   Shinkawa, K ^a   Tani, K ^a   Sone, S ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bronchial asthma; Inhaled corticosteroids; Long term follow up; Peak expiratory flow; Pranlukast

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; PRANLUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LUNG FUNCTION; MALE; MEDICAL RECORD; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TACHYPHYLAXIS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; RETROSPECTIVE STUDIES; TIME; TREATMENT OUTCOME;

EID: 1142273101     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-003-1044-8     Document Type: Article

References (18)

1. American Thoracic Society (1987) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136:225-244
2. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL (1993) A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J 6:877-885
3. Barnes NC, Pujet JC (1997) Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 52:523-527
4. Broide DH (2001) Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108:S65-S71
5. Busse WW, Lemanske Jr RF (2001) Asthma. N Engl J Med 344:350-362
6. Drazen JM, Israel E, O Byrne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206
7. Grossman J, Faiferman I, Dubb JW, Tompson DJ, Busse W, Bronsky E, Montanaro A, Southern L, Tinkelman D (1997) Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 34:321-328
8. Kohrogi H, Iwagoe H, Fujii K, Hamamoto J, Fukuda K, Hirata N, Kawano O, Matsumoto M, Suga M, Ando M (1999) The role of cysteinyl leukotrienes in the pathogenesis of asthma: clinical study of leukotriene antagonist pranlukast for 1 year in moderate and severe asthma. Respirology 4:319-323
9. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF (1999) Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 160:1862-1868
10. National Heart, Lung, and Blood Institute, National Institutes of Health (1995) Establish medication plans for long-term management. In: Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. NIH Publications no. 95-3659. National Institutes of Health, Bethesda, 77-102
11. Obase Y, Shimoda T, Tomari S, Mitsuta K, Fukushima C, Kawano T, Matsuse H, Kohno S (2001) Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year follow-up study. Ann Allergy Asthma Immunol 87:43-47
12. Price DB, Hernandez D, Magyar P, et al (2003) Randomised controlled trial of montelukast plus inhaled budesonide versus double-dose inhaled budesonide in adult patients with asthma. Thorax 58:211-216
13. Robinson DS, Campbell D, Barnes PJ (2001) Addition of leukotriene antagonists to therapy in chronic persisitent asthma: a randomized double-blind placebo-controlled trial. Lancet 357:2007-2011
14. Rosenwasser LJ (1999) Leukotriene modifiers: new drugs, old and new reactions. J Allergy Clin Immunol 103:374-375
15. Suissa S, Ernst P (2001) Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 107:937-944
16. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, Takizawa T, Konno K, on behalf of The Tokyo Joshi-Idai Asthma Research Group (1997) Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 155:1235-1240
17. Yoo SH, Park SH, Song JS, Kang KH, Park CS, Yoo JH, Choi BW, Hahn MH (2001) Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4-week randomized multicentre controlled trial. Respirology 6:15-21
18. Wada K, Minoguchi K, Kohno Y, et al (2000) Effect of a leukotriene receptor antagonist, pranlukast hydrate, on airway inflammation and airway hyperresponsiveness in patients with moderate to severe asthma. Allergol Int 49:63-68